People across the globe are looking forward to longer life expectancies. The aim is to find new ways to treat solid tumors.
The establishment of anti-tumor immunity requires the multiplication and differentiation of the immune system's cells. Specific interactions between different T cells in the body are what determines this process. Existing tumors vaccines rely on random interactions with the body's immune system. Inappropriate interactions could lead to the suppression of other immune responses.
Although immune checkpoint-based immunotherapy has been shown to have great potential, only a small percentage of patients fully respond, and the relevant mechanisms need to be further explored. The delivery method is complicated.
In a breakthrough development, a team of scientists led by Narat Muzayyin Chair Professor Chen Xiaoyuan from the NUS Yong Loo Lin School of Medicine and ProfessorLiu Gang from Xiamen University has formulated a novel vaccine which showed high efficacy in the treatment of solid tumors. The immunity provided by this prevents the patient from being exposed to the same types of tumors. The vaccine was used on melanoma tumors. The results are published in a journal.
The team was able to engineer a cell that could be used to create an immune system that could fight tumors. The team decided to call it ASPIRE due to the use of the vaccine platform.
Traditional vaccine methods could not be used in a way that the ASPIRE vaccine system can. This mode of presentation improves the effectiveness of the vaccine compared to other vaccines currently on the market. ASPIRE's superior anti- tumor immune capabilities can be achieved by both previously un exposed T cells and exhausted T cells.
Prof Chen said that they are excited about the platform technology's potential for further application in other diseases, such as chronic viral infections, in which T-cell exhaustion often occurs during infection and prevents the optimal viral control. The team hopes to establish a standard operating procedure for scaled synthesis of the vaccine with proper quality control.
Speaking independently on the study, Professor Chng Wee Joo, Senior Consultant of the Division of Haematology at the Department of Haematology-Oncology in the National University Cancer Institute, Singapore and myeloma specialist said: "The field of cancer immunotherapy is offering tremendous hope to cancer patients. However, there are some shortcomings with the current technologies. The present innovation from Prof Chen and his colleagues overcome some of these deficiencies and improved the effectiveness and
The immune response is sustainable. The advance will have an impact on patients.
All Rights Reserved © 2024
